Why #Paxlovid is a Just-in-Time Breakthrough - by Eric Topol
Omicron doesn’t evade this drug’s effect. There’s only one 1 mutation for this variant in its main protease and, as would be anticipated, testing paxlovid in the lab demonstrated no diminution of its activity against Omicron.
The 2 clinical trials were presented via press release this week (yes, suboptimal but so far this company’s press releases have matched up with subsequent preprints and publications during the pandemic) .
The results from the randomized, placebo-controlled completed trial of high risk participants is summarized below.